Therefore, curcumin’s predicted ability to simultaneously inhibit GSK3β—a core target in both BD and insulin signaling—and suppress the p38 MAPK/NFκB inflammatory axis suggests it may offer a more integrated therapeutic strategy, addressing both the neuro-regulatory and metabolic dysfunctions inherent to the comorbidity. Here, GSK3B is linked to Behcet disease.